These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9130818)

  • 1. Hirano bodies and Alzheimer's disease.
    Mitake S; Ojika K; Hirano A
    Kaohsiung J Med Sci; 1997 Jan; 13(1):10-8. PubMed ID: 9130818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible implication of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano body formation.
    Mitake S; Katada E; Otsuka Y; Matsukawa N; Iwase T; Tsugu T; Fujimori O; Ojika K
    Neuropathol Appl Neurobiol; 1996 Oct; 22(5):440-5. PubMed ID: 8930956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano bodies.
    Mitake S; Ojika K; Katada E; Otsuka Y; Matsukawa N; Fujimori O
    Neuropathol Appl Neurobiol; 1995 Feb; 21(1):35-40. PubMed ID: 7770119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of epitopes shared by Hirano bodies and neurofilament proteins in normal and Alzheimer's disease hippocampus.
    Schmidt ML; Lee VM; Trojanowski JQ
    Lab Invest; 1989 Apr; 60(4):513-22. PubMed ID: 2468822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presence of FAC1 protein in Hirano bodies.
    Jordan-Sciutto K; Dragich J; Walcott D; Bowser R
    Neuropathol Appl Neurobiol; 1998 Oct; 24(5):359-66. PubMed ID: 9821166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquilin-1 immunoreactivity is concentrated on Hirano bodies and dystrophic neurites in Alzheimer's disease brains.
    Satoh J; Tabunoki H; Ishida T; Saito Y; Arima K
    Neuropathol Appl Neurobiol; 2013 Dec; 39(7):817-30. PubMed ID: 23421764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunolocalization of Smurf1 in Hirano bodies.
    Makioka K; Yamazaki T; Takatama M; Ikeda M; Okamoto K
    J Neurol Sci; 2014 Jan; 336(1-2):24-8. PubMed ID: 24238996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.
    Münch G; Cunningham AM; Riederer P; Braak E
    Brain Res; 1998 Jun; 796(1-2):307-10. PubMed ID: 9689484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of actin with Hirano bodies.
    Goldman JE
    J Neuropathol Exp Neurol; 1983 Mar; 42(2):146-52. PubMed ID: 6186777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The involvement of hippocampal cholinergic neurostimulating peptide and its precursor in Alzheimer pathogenesis].
    Matsukawa N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Jun; 34(3):93-100. PubMed ID: 25076779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer's disease.
    Gibson PH; Tomlinson BE
    J Neurol Sci; 1977 Aug; 33(1-2):199-206. PubMed ID: 903782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hirano bodies and related neuronal inclusions.
    Hirano A
    Neuropathol Appl Neurobiol; 1994 Feb; 20(1):3-11. PubMed ID: 8208338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-cleaved actin (fractin) immunolabelling of Hirano bodies.
    Rossiter JP; Anderson LL; Yang F; Cole GM
    Neuropathol Appl Neurobiol; 2000 Aug; 26(4):342-6. PubMed ID: 10931367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hirano bodies accumulate C-terminal sequences of beta-amyloid precursor protein (beta-APP) epitopes.
    Munoz DG; Wang D; Greenberg BD
    J Neuropathol Exp Neurol; 1993 Jan; 52(1):14-21. PubMed ID: 7678852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: distinction from Alzheimer disease.
    Takeda T; Uchihara T; Arai N; Mizutani T; Iwata M
    Acta Neuropathol; 2009 Jan; 117(1):35-44. PubMed ID: 19002475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cytosolic inclusion bodies that consist of splice variants that lack exon 5 of the presenilin-2 gene differ obviously from Hirano bodies observed in the brain from sporadic cases of Alzheimer's disease patients.
    Manabe T; Katayama T; Sato N; Kudo T; Matsuzaki S; Imaizumi K; Tohyama M
    Neurosci Lett; 2002 Aug; 328(2):198-200. PubMed ID: 12133587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hirano body filaments contain actin and actin-associated proteins.
    Galloway PG; Perry G; Gambetti P
    J Neuropathol Exp Neurol; 1987 Mar; 46(2):185-99. PubMed ID: 3029338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hirano body expression impairs spatial working memory in a novel mouse model.
    Furgerson M; Clark JK; Crystal JD; Wagner JJ; Fechheimer M; Furukawa R
    Acta Neuropathol Commun; 2014 Sep; 2():131. PubMed ID: 25178488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hirano bodies contain tau protein.
    Galloway PG; Perry G; Kosik KS; Gambetti P
    Brain Res; 1987 Feb; 403(2):337-40. PubMed ID: 3103867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathology of the cytoskeleton in Alzheimer's disease and disorders related to this disease].
    Seitelberg F; Lassmann H
    Gac Med Mex; 1990; 126(5):367-73. PubMed ID: 1966495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.